Premium
Clinical and biological significance of hepatoma‐derived growth factor in Ewing's sarcoma
Author(s) -
Yang Yang,
Li Hui,
Zhang Fenfen,
Shi Huijuan,
Zhen Tiantian,
Dai Sujuan,
Kang Lili,
Liang Yingjie,
Wang Jin,
Han Anjia
Publication year - 2013
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.4241
Subject(s) - sarcoma , ewing's sarcoma , cancer research , osteosarcoma , growth factor , cell growth , biology , medicine , pathology , receptor , genetics
We sought to investigate the clinicopathological significance and biological function of hepatoma‐derived growth factor ( HDGF ) in Ewing's sarcoma. Our results showed that HDGF expression is up‐regulated in Ewing's sarcoma. Nuclear HDGF expression is significantly associated with tumour volume ( p < 0.001), metastases at diagnosis ( p < 0.001), low overall survival rate ( p < 0.001) and low disease‐free survival rate ( p < 0.001). HDGF knock‐down results in significant reduction of Ewing's sarcoma cell growth, proliferation and enhances tumourigenesis, both in vitro and in vivo . Meanwhile, HDGF knock‐down causes cell cycle arrest and enhanced sensitization to serum starvation‐induced apoptosis. Furthermore, recombinant HDGF promotes proliferation and colony formation of Ewing's sarcoma cells. Ninety‐eight candidate HDGF downstream genes were identified in Ewing's sarcoma cells using cDNA microarray analysis. In addition, we found that HDGF knock‐down inhibited FLI1 expression in Ewing's sarcoma cells at the mRNA and protein levels. Our findings suggest that HDGF exhibits oncogenic properties and may be a novel prognostic factor in Ewing's sarcoma. Targeting HDGF might be a potential therapeutic strategy for Ewing's sarcoma. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.